Longeveron (NASDAQ: LGVN; LGVNR) Study Survival Data Reported at AHA’s Scientific Sessions
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS),...
Longeveron (NASDAQ: LGVN; LGVNR) Announces Plans to Release Q3 2023 Financial Report
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, has announced plans to report its financial results...